Laddar...
Darolutamide: a novel androgen-signaling agent in nonmetastatic castration-resistant prostate cancer
ARAMIS is an international Phase III trial demonstrating the beneficial role of darolutamide, a novel anti-androgen that has been found to prolong metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer. Darolutamide is a novel nonsteroidal androgen receptor antagonis...
Sparad:
| I publikationen: | Asian J Androl |
|---|---|
| Huvudupphovsman: | |
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Publicerad: |
Wolters Kluwer - Medknow
2019
|
| Ämnen: | |
| Länkar: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6958984/ https://ncbi.nlm.nih.gov/pubmed/31249268 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4103/aja.aja_52_19 |
| Taggar: |
Lägg till en tagg
Inga taggar, Lägg till första taggen!
|